Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

What Was Tested

The paper reports a study of Retatrutide, published as a randomized controlled trial.

Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

Because people in this Retatrutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Retatrutide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Retatrutide could be set against what happens without it.

Groups ran in parallel: each of the participants stayed in one arm throughout.

TRIUMPH-2 was a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial conducted at 92 medical and research centres and hospitals across eight countries.

This trial is registered with ClinicalTrials.gov, NCT05929079 (completed).

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Obesity, Hypoglycemic Agents, Glucagon-Like Peptides, Fatty Acids, Peptides and Glucagon-Like Peptide 1.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Retatrutide.

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Lancet (London, England)), a journal based in England.

More context: the Retatrutide compound page, all human trials.